Gionchetti Paolo, Rizzello Fernando, Lammers Karen-M, Morselli Claudia, Sollazzi Lucia, Davies Samuel, Tambasco Rosy, Calabrese Carlo, Campieri Massimo
Department of Internal Medicine and Gastroenterology, Bologna, Italy.
World J Gastroenterol. 2006 Jun 7;12(21):3306-13. doi: 10.3748/wjg.v12.i21.3306.
Many experimental and clinical observations suggest that intestinal microflora plays a potential role in the pathogenesis of inflammatory bowel disease (IBD). Manipulation of the luminal content using antibiotics or probiotics represents a potentially effective therapeutic option. The available studies do not support the use of antibiotics in ulcerative colitis (UC). Antibiotics are effective in treating septic complications of Crohn's disease (CD) but their use as a primary therapy is more controversial, although this approach is frequently and successfully adopted in clinical practice. There is evidence that probiotic therapy may be effective in the prevention and treatment of mild to moderate UC. In contrast, a lack of successful study data at present precludes the widespread use of probiotics in the treatment of CD. Both antibiotics and probiotics appear to play a beneficial role in the treatment and prevention of pouchitis and further trials are warranted to fully quantify their clinical efficacy.
许多实验和临床观察表明，肠道微生物群在炎症性肠病（IBD）的发病机制中发挥着潜在作用。使用抗生素或益生菌来调控肠腔内容物是一种潜在有效的治疗选择。现有研究不支持在溃疡性结肠炎（UC）中使用抗生素。抗生素对治疗克罗恩病（CD）的败血症并发症有效，但其作为主要治疗方法更具争议性，尽管这种方法在临床实践中经常被成功采用。有证据表明，益生菌疗法可能对预防和治疗轻至中度UC有效。相比之下，目前缺乏成功的研究数据，阻碍了益生菌在CD治疗中的广泛应用。抗生素和益生菌似乎在治疗和预防储袋炎方面都发挥着有益作用，有必要进行进一步试验以全面量化它们的临床疗效。
